Evidence map›Paper›PMID 27225498›Full record

ReviewCurrent topics in behavioral neurosciences2018

Discriminative Stimulus Properties of Opioid Ligands: Progress and Future Directions.

Eduardo R Butelman, Mary Jeanne Kreek

Open access · hybridAbstract readReview
PubMed Publisher
In one paragraph

Review in Current topics in behavioral neurosciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Eduardo R ButelmanLaboratory on the Biology of Addictive Diseases, The Rockefeller University, 1230 York Avenue, Box 171, New York, NY, 10065, USA. butelme@rockefeller.edu.
Mary Jeanne KreekLaboratory on the Biology of Addictive Diseases, The Rockefeller University, 1230 York Avenue, Box 171, New York, NY, 10065, USA.
Rockefeller University · US

Funding

ULTRASTUCTURE, RECEPTORS, AND GENE EXPRESSIONP60DA005130 · NIDA · ROCKEFELLER UNIVERSITY · PI KREEK, MARY J · 2002 to 2012
$30.6M
SYSTEMICALLY ADMINISTERED DYNORPHINSR01DA011113 · NIDA · ROCKEFELLER UNIVERSITY · PI BUTELMAN, EDUARDO R · 1996 to 2002
$976k
kappa-agonist effects of the hallucinogen Salvinorin AR01DA017369 · NIDA · ROCKEFELLER UNIVERSITY · PI BUTELMAN, EDUARDO R · 2005 to 2008
$814k
NIDA NIH HHS P60 DA005130NIDA NIH HHS R01 DA011113NIDA NIH HHS R01 DA017369
6 · The paper itself

Abstract

Opioid receptors (MOP-r, KOP-r, DOP-r, as well as NOP-r) and their endogenous neuropeptide agonist systems are involved in diverse neurobiological and behavioral functions, in health and disease. These functions include pain and analgesia, addictions, and psychiatric diseases (e.g., depression-, anxiety-like, and stress-related disorders). Drug discrimination assays have been used to characterize the behavioral pharmacology of ligands with affinity at MOP-r, KOP-r, or DOP-r (and to a lesser extent NOP-r). Therefore, drug discrimination studies with opioid ligands have an important continuing role in translational investigations of diseases that are affected by these neurobiological targets and their pharmacotherapy.

Indexed as

Analgesics, OpioidAnimalsDiscrimination, PsychologicalHumansLigandsNarcotic AntagonistsReceptors, OpioidAnalgesics, OpioidLigandsNarcotic AntagonistsReceptors, OpioidAddictionAnalgesiaDrug discriminationOpioidPrescription opioids

Identifiers

PMID27225498
OpenAlexW2403586582

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.